renee a reijo pera, phd stanford university … renee a reijo pera, phd stanford university...

1

Renee A Reijo Pera, PhD Stanford University

EDUCATION

PROFESSIONAL POSITIONS, HONORS AND AWARDS

Professional Positions 2012- George D Smith Professor of Stem Cell Biology & Regenerative Medicine; Institute for Stem Cell Biology and Regenerative Medicine, Departments of Genetics and Obstetrics and Gynecology; Director, Center for Reproductive and Stem Cell Biology; Director, Center for Human Pluripotent Stem Cell Research and Education; Stanford University 2013- CoDirector Stanford:NIST ABMS (Advances in Biological Measurement Sciences

program (other CoDirectors: Norbert Pelc (BioEngineering), Tom Baer (Applied Physics and Marc Salit (NIST))

2013- Consultant, US Food and Drug Administration (FDA); Cellular, Tissue and Gene Therapies

2013- Founder; NovoVia, Inc; Palo Alto, CA (private-donor backed initiative intended to translate findings in the laboratory to use of stem cells to restore fertility in boys with cancer and other species (including endangered)

2012- Founder, Board of Directors; Cellogy, Inc, Menlo Park, CA (private-donor backed initiative intended to translate findings in the laboratory to imaging algorithms to predict neurodegeneration

2011- Founder, Scientific Advisor, Board of Directors; StemGyn, Inc, Palo Alto, CA (a private-donor backed initiative intended to translate findings in the laboratory to applications in women’s health)

2010- Director, Stanford University Interdisciplinary Graduate Program in Stem Cell Biology and Regenerative Medicine

2010- Founder, Scientific Advisor, Board of Directors; Auxogyn, Inc, Menlo Park, CA (a venture backed startup that is conducting clinical trials via intellectual property for embryo diagnosis generated in the Reijo Pera laboratory)

2003-2007 CoDirector, University of California at San Francisco (UCSF) Human Development Center; Associate Professor, Institute for Human Genetics; Institute for Regeneration Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Departments of Physiology and Urology; Program in Cancer Genetics 1997-2003 Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Department of Physiology, Department of Urology; Institute for Human Genetics; Institute for Regeneration Medicine (formerly Development and Stem Cell Biology), Program in Cancer Genetics, University of California at San Francisco 1995 Instructor: Biology 734: Human Genetics; Dr. David Baltimore, Course Coordinator Department of Biology; Massachusetts Institute of Technology 1993-97 Damon-Runyan Fellow, Whitehead Institute for Biomedical Research Laboratory of David Page

INSTITUTION AND LOCATION

DEGREE

YEAR SCIENTIFIC DISCIPLINE and MENTOR

University of Wisconsin at Superior (UWS) Kansas State University

B.S. M.S.

1983 1987

Biology (Daryl Kaufmann) Entomology (Ted Hopkins)

Cornell University Ph.D. 1993 Molecular Cell Biology (Tim Huffaker) Massachusetts Institute of Technology (MIT)

Postdoc 1993-97 Human Genetics (David Page)

2

1988-93 Doctoral Graduate Student, Department of Biochemistry, Molecular and Cell Biology, Laboratory of Dr Timothy Huffaker (Thesis Research Subject: Mitotic and meiotic mutants in Saccharyomyces cerevisiae) 1984-87 MS Graduate Student, Department of Entomology, Kansas State University, Manhattan, KS, Laboratory of Dr Theodore Hopkins (Thesis Research Subject: Calcification in the Face Fly, Musca autumnalis)

Selected Honors and Awards:

George D Smith Endowed Chair of Institute for Stem Cell Biology and Regenerative Medicine Time Magazine’s Top 10 Biomedical Breakthroughs (December, 2010; for imaging algorithms) Newsweek 20 Influential Women in America (September, 2006) Stanford Nominee: 2014 International Gairdner Award for Outstanding Contributions to Human

Biology (September 2013) Recognized International Top Ten Projects in Reproductive Medicine for breakthrough papers

(September 2013) Adjunct Professor status; Center for iPS Cell Research and Application; Kyoto University, Japan (2009-2011) Honorary Doctorate of Humane Letters (University of Wisconsin – Superior (May, 2009)) Stanford President’s Office Faculty Fellows - Stanford University (2010-present) IVI International Award for Career Impact in Reproductive Medicine (April, 2011; Valencia,

Spain) Shulman Award in Health Research; University of Pittsburg (2011) Australian Society for Reproductive Biology Founder’s Award (Sydney, Australia; October, 2010) Keiser Biology Award – Ohio Northern University (September, 2010) American Society for Reproductive Medicine (ASRM) Bruce Stewart Research Award (October,

2007) UCSF:Coro Center for Leadership Training (January – May; 2006) University of California (UCSF) Graduate Student Association, Outstanding Faculty Mentorship

Award (May, 2005) American Stem Cell Research Foundation Award (2004) Searle Scholar (September 1998-2001) Sandler Award in Basic Science (UCSF, 1999-2000) Innovations in Basic Science Award (UCSF, 1998-9) Damon Runyon/Walter Winchell Postdoctoral Fellowship (Whitehead Institute at MIT; 1993-6) U.S. Army Biotechnology Graduate Fellowship (1991-1993) Cornell Outstanding Teacher Award (1988) Cornell Graduate Travel Award (1988) DuPont Teaching Fellow (1989) Sigma Xi Research Excellence Award (1985) Lakehead Pipeline Association Scholarship (1982) Magne Cum Laude Honors (1983) SIGNIFICANT PROFESSIONAL ACTIVITIES

At Stanford (since 2007): Chair, Stanford Committee on Appointments and Promotions (“Tenure Committee”; School of

Medicine; 2011 – present) Steering Committee and CoDirector; Joint Stanford and National Institutes for Standards and

Technology (NIST) Measurement Sciences Center (2010-present) Elected Senator, 45th Stanford University-wide Faculty Senate (2011 – present) Member, Directors of Graduate Studies (DGS), Stanford University (2010 – present) Director of Education – Stanford University Program in Regenerative Medicine (2010-present)

3

External Scientific Advisory Committee, Oregon Health Sciences University – West Campus (2009-present)

Stanford Undergraduate Mentor and Advisor (2011 – present) Invited Member, Stanford Leadership Fellows (2010-2012) a group of university leaders who

meet monthly to probe issues in education (use of online versus classroom learning, role of laboratory-based versus didactic learning, fundraising for innovation and others)

Major Search Committee Membership in Last Two Years for Chair, Department of Medicine; Chair, Department of Dermatology; Director, Women’s Health@Stanford University (2010-2012)

Chair, Search Committee: Biocomputation, Institute for Stem Cell Biology & Regenerative Medicine (current)

Steering Committee, NICHD Specialized Cooperative Centers Program in Reproduction and Infertility Research (2011-present)

Steering Committee Member, Progenitor Cell Biology Consortium (PCBC; National Heart, Lung and Blood Institute (NHLBI)) (2011 – present)

Advisory Panel, Reproductive Biology, National Institutes of Child Health and Human Development (NICHD; 2010)

Advisory Panel, NICHD Vision Process, Fetal Outcomes (2011) Admissions Committee; Stanford University School of Medicine Medical Students (2012 –

present) Admissions Committee; Stanford Graduate Program in Stem Cell Biology and Regenerative

Medicine (2011 – present) Member, Stanford University Stem Cell Research Oversight (SCRO) committee, 2007-2010 Panelist – Stanford University Law School Forum (with written guidelines) on human stem cell

issues (May, 2009) Board of Directors (and Co-Founder), Auxogyn, Inc, (2010-present), a venture-backed start-up

that has translated basic research in the Reijo Pera laboratory to clinical improvements in human reproductive health via diagnosis of embryos with potential for development

Cofounder and Advisor; The Stem Cell Advisors (a national non-profit organization to advice on stem cell matters); 2009-2011

Organizer; Cold Spring Harbor Laboratory (CSHL) Meeting “Germ Cell Development” in 2008 Loreal Women in Science Program Moderator (February 2007)

Other past professional activities (prior to Stanford University): Women’s 98 Forum (Betty Ford Center; Palm Springs, CA), 1998 Consultant for International Quality Control Assessment Programme for Y-Chromosomal

Microdeletions (Institute for Reproductive Medicine Munster Germany), 1999-2000 Ad Hoc Member of the Reproductive Biology Study Section (NICHD, NIH), 2001-2002 Ad Hoc Member of the U54 Contraceptive Study Section (RFA; NICHD, NIH), 2002 Ad Hoc Member of the Mammalian Genetics Study Section on Mouse Phenotyping (RFA;

NIGM, NIH; 2002) UC Chancellor’s Advisory Committee on the Status of Women (CACSW) Admission Committee for Graduate Students in the Program in Biological Sciences (UCSF) Admissions Committee for Medical Genetics Fellows (1997-1998) Panelist for UCSF Foundation Wellness Day (Palace Hotel; SF; May 1999) Member UCSF Human Genetics Course Planning Committee (Jane Gitscher, chair, 1999) Member UCSF BioMedical Sciences Genetics Course Committee (Joe Gray, chair, 2001-2002) Steering Committee - Center for Reproductive Sciences (1999 – present) Member of the Academic Senate Committee on Research (COR; 2001-present) Member of the Steering Committee for UCSF Developmental and Stem Cell Biology Program

(2002-present)

4

Represented UCSF for Minority Graduate Program Recruitment by Presentations (UC-Irvine, November 1999; UCSF Faculty Host, December 2001; UCSF Faculty Research Speaker, February 2002)

Panelist for UCSF Foundation Presentation, October 2002, “Stem Cells” (Home of John and Francis Bowes)

Steering Committee; Developmental and Stem Cell Biology Program (2002 – present) Planning Committee; Proposition 71 Human Embryonic Stem Cell Application (2004 – present) Core Member; UCSF Center for Human Genetics (2004 – present) Panelist; UCSF Diabetes Research Program (Stem Cells and Diabetes; May 2005) Co-Organizer; UCSF BioMedical Sciences (BMS) Retreat (with Kevin Shannon, MD; 2005) Presentation of Stem Cell Research Opportunities (Dr. Kessler (Dean of School of Medicine)

hosted Minister of Health, India (Dr. Anbumani Ramadoss)); June 2005 Member; UCSF Oocyte, Embryo, and Stem Cell Research (OESCR) Committee; June 2005 –

present Teacher/Coordinator; “UCSF Mini-Medical School Curriculum;” June 2005 and June 2006 Scientific Reviewer for the Italian Funding Agency - Fondazione Telethon; Milano, Italy; June

2002 - 2004 Continuing Medical Education Instructor; Clinical Infertility and Reproductive Endocrinology (San Francisco, CA; April, 2002) Member of the Faculty of 1000, a group of faculty providing reviews of relevant literature in area

of expertise (www.facultyof1000.com) Permanent Member of the CMIR (Cellular, Molecular and Integrative Reproduction) Study

Section (NICHD, NIH – June, 2004 to 2008) Coalition Member to Promote Proposition 71 – Women’s Advocacy Groups; Medical and

Scientific Community Leaders (2004-present) Scientific Reviewer for the Research Funding and Policy Division of the Health Research Board

in Ireland (2005) Scientific Reviewer for the Research Funding for NSERC of Canada; 2005 CoDirector; Frontiers in Human Embryonic Stem Cells Course (Stanford University, School of

Medicine; June 2005) Scientific Education on Derivation and Propagation of hESCs; US Senate Appropriations

Committee Staff Meeting (February 2005) Scientific Reviewer for the Programming Committee for the International Embryo Transfer

Society; Annual Meeting, Orlando, FL (January 2006) Scientific Reviewer for the Illinois Regenerative Medicine Institute (April 2006) College of Reviewers for the Canada Research Chairs Program; 2006 International Advisory Committee on Stem Cells and Germ Cell Development (Hinxton, UK; 2008) Scientific Advisor: Reproductive Biology and Medicine Oversight; Centre of Reproductive Medicine and Andrology; Muenster, Germany

Editorial Boards: Stem Cells; 2006-present; Human Molecular Genetics; 2010-present; PLoS One; 2009 – present; Journal of Assisted Reproduction and Genetics (Associate Editor); 2010-present PEER-REVIEWED PUBLICATIONS (invited publications not listed)

1. Awe JP, Lee PC, Ramathal C, Vega-Crespo A, Durruthy-Durruthy J, Cooper A, Karumbayaram S, Lowry WE, Clark AT, Zack JA, Sebastiano V, Kohn DB, Pyle AD, Martin MG, Lipshutz GS, Phelps PE, Reijo Pera RA, Byrne JA. (2013) Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Research and Therapy 4, 87.

5

2. Chen AA, Tan L, Suraj V, Reijo Pera R, Shen S (2013) Biomarkers identified with time-lapse imaging: discovery, validation, and practical application. Fertility Sterility 99, 1035-43.

3. Wen Y, Wani P, Zhou L, Baer T, Phadnis SM, Reijo Pera RA, Chen B (2013) Reprogramming of fibroblasts from older women with pelvic floor disorders alters cellular behavior associated with donor age. Stem Cells Translational Medicine 2, 118-28.

4. RA Jalil, NF Huang, J Kim, J Herold, KS Volz, TS Park, JC Lee, ET Zambidis, RA Reijo Pera and JP Cooke (2013) Human induced pluripotent stem cell-derived endothelial cells exhibit functional heterogeneity. American Journal of Translational Research 5, 21-35

5. Chavez SL, Loewke KE, Han J, Moussavi F, Colls P, Munne S, Behr B, and Reijo Pera RA

(2012) Dynamic blastomere behavior reflects human embryo ploidy by the four-cell stage. Nature Communications 3, 1251.

6. Vega Crespo A, Awe JP, Reijo Pera R, Byrne JA (2012) Human skin cells that express stage-specific embryonic antigen 3 associate with dermal tissue regeneration. Bioresearch Open Access 1, 25-33.

7. Kawamura K, Chen Y, Shu Y, Cheng Y, Qiao J, Behr B, Reijo Pera RA and Hsueh AJ (2012) Promotion of early embryonic development and blastocyst outgrowth in vitro using autocrine/paracrine growth factors. PLoS ONE 7, e49328.

8. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA (2012) Genetic markers of ovarian follicle number and menopause in women of multiple ethnicities. Human Genetics 131, 1709-24.

9. J Lee, Sayed N et al (2012) Activation of innate immunity is required for efficient nuclear reprogramming. Cell 51, 547-58.

10. Chung C, Anderson E, Reijo Pera RA, Pruitt B and Heilshorn SC (2012) Hydrogel crosslinking density regulates temporal contractility of human embryonic stem cell-derived cardiomyocytes in 3D cultures. Soft Matter (in press).

11. Niakan KK, Han J, Pedersen RA, Simon C, and Reijo Pera RA (2012) Human pre-implantation embryo development. Development 139, 829-41.

12. Byers B, Lee HL, and Reijo Pera R (2012) Modeling Parkinson's disease using induced pluripotent stem cells. Current Neurology and Neurosciences Reports 12, 237-42.

13. Quarto N, Leonard B, Li S, Marchand M, Anderson E, Behr B, Francke U, Reijo-Pera R, Chiao E, and Longaker MT (2012) Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells. Proceedings National Academy of Sciences 109, 215-20.

14. Rosen MP, Johnstone E, McCulloch CE, Schuh-Huerta SM, Sternfeld B, Reijo-Pera RA, and Cedars MI (2012) A characterization of the relationship of ovarian reserve markers with age. Fertility & Sterility 2012 97, 238-43.

15. Medrano JV, Ramathal C, Nguyen HN, Simon C, and Reijo Pera RA (2012) Divergent RNA-binding proteins, DAZL and VASA, induce meiotic progression in human germ cells derived in vitro. Stem Cells 30, 441-51.

16. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, and Reijo Pera RA. (2012) Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Human Reproduction 27, 594-608

17. Byers B, Cord B, Nguyen HN, Schüle B, Fenno L, Lee PC, Deisseroth K, Langston JW, Reijo Pera RA, and Palmer TD (2011) SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One 6, e26159.

18. Rufaihah AJ, Huang NF, Jamé S, Lee JC, Nguyen HN, Byers B, De A, Okogbaa J, Rollins M, Reijo Pera R, Gambhir SS, and Cooke JP (2011) Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arteriosclerosis, Thrombosis, and Vascular Biology 31, e72-9.

6

19. Kalista T, Freeman HA, Behr B, Reijo Pera RA, and Scott CT (2011) Donation of embryos for human development and stem cell research. Cell Stem Cell 8, 360-2.

20. Chung J, Dash R, Kee K, Barral JK, Kosuge H, Robbins RC, Nishimura D, Reijo-Pera RA, and Yang PC (2011) Theranostic effect of serial manganese-enhanced magnetic resonance imaging of human embryonic stem cell derived teratoma. Magnetic Resonance in Medicine [Epub ahead of print; Dec 21]

21. Johnstone EB, Rosen MP, Neril R, Trevithick D, Sternfeld B, Murphy R, Addauan-Andersen C, McConnell D, Reijo Pera RA, and Cedars MI (2010) The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. Journal of Clinical and Endocrinological Metabolism 95, 4965-72.

22. Siemen H, Colas D, Heller HC, Brüstle O, and Reijo Pera RA (2011) Pumilio-2 function in the mouse nervous system. PLoS One 6, e25932.

23. Chung J, Kee K, Barral JK, Dash R, Kosuge H, Wang X, Weissman I, Robbins RC, Nishimura D, Quertermous T, Reijo-Pera RA, and Yang PC (2011) In vivo molecular MRI of cell survival and teratoma formation following embryonic stem cell transplantation into the injured murine myocardium. Magnetic Resonance in Medicine 66,1374-81.

24. Batista LF, Pech MF, Zhong FL, Nguyen HN, Xie KT, Zaug AJ, Crary SM, Choi J, Sebastiano V, Cherry A, Giri N, Wernig M, Alter BP, Cech TR, Savage SA, Reijo Pera RA, and Artandi SE. (2011) Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474, 399–402.

25. HN Nguyen, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schuele B, Dolmetsch RE, Langston W, Palmer TD, and Reijo Pera RA (2011) LRRK2 mutant iPSC-Derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8: 1–14.

26. Julaton VT and Reijo Pera RA (2011) NANOS3 function in human germ cell development. Human Molecular Genetics 20, 2238-50.

27. Panula S, Medrano JV, Kee K, Bergstrom R, Nguyen HN, Byers B, Wilson KD, Wu JC, Simon C, Hovatta O, and Reijo Pera RA (2010) Human germ cell differentiation from fetal- and adult-derived induced pluripotent stem cells. Human Molecular Genetics 20, 752-62.

28. Tang C, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR, Inlay MA, Ardehali R, Chavez SL, Reijo Pera RA, Behr B, Wu JC, Weissman IL, and Drukker M (2011) An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nature Biotechnology 29, 829-34.

29. Schuh-Huerta SM and Reijo Pera RA (2011) Reproductive biology: bone returns the favour. Nature 472, 46-7.

30. Wong CC, Loewke KE, Bossert NL, Behr B, De Jonge CJ, Baer TM, and Reijo Pera RA. (2010) Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nature Biotechnology 28:1115-21.

31. Rosen MP, Sternfeld B, Schuh-Huerta SM, Reijo Pera RA, McCulloch CE, and Cedars MI (2010) Antral Follicle Count – absence of significant midlife decline. Fertility & Sterility 94:2182-2185.

32. McElroy SL, Byrne JA, Chavez SL, Behr B, Hsueh AJ, Westphal LM, and Reijo Pera RA (2010) Parthenogenic blastocysts derived from cumulus-free in vitro matured human oocytes. PLoS One 5: e10979.

33. Kee K, Flores M, Cedars MI, and Reijo Pera RA (2010) Human primordial germ cell formation is diminished by exposure to environmental toxicants acting through the AHR signaling pathway. Toxicological Sciences 117, 218-24.

34. Kee K, Reijo Pera RA, and Turek PJ (2010) Testicular germ line stem cells. Nature Reviews, Urology 7: 94-100.

35. Rosen MP, Johnstone EB, Gillham SJ, Modan AE, Lipshutz AK, Reijo-Pera RA, and Cedars MI (2010) Is antral follicle count a genetic trait? Menopause 17:109-13.

7

36. Kee K, Angeles VT, Flores M, Nguyen HN, and Reijo Pera RA (2009) Human DAZL, DAZ and BOULE genes modulate primordial germ cell and haploid gamete formation. Nature 462, 222-5.

37. Nicholas CR, Haston KM, and Reijo Pera RA (2010) Intact fetal ovarian cord formation promotes mouse oocyte survival and development. BMC Developmental Biology 10, 2.

38. Zhang L, Blackman BE, Schonemann MD, Zogovic-Kapsalis T, Pan X, Tagliaferri M, Harris HA, Cohen I, Reijo Pera RA, Mellon SH, Weiner RI, and Leitman DC (2010) Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons. PLoS One 5, e11791.

39. Byrne JA, Nguyen HN, and Reijo Pera RA (2009) Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts. PLoS One 4, e7118.

40. Schuele B, Reijo Pera RA, and Langston JW (2009) Can cellular models revolutionize drug screening in Parkinson’s disease? Biochem Biophys Acta 1792, 1043-51.

41. Nicholas CR, Haston KM, Grewall AK, Longacre TA, and Reijo Pera RA (2009) Transplantation directs oocyte maturation from embryonic stem cells and provides a therapeutic strategy for female infertility. Human Molecular Genetics 18:4376-89.

42. Haston KM, Tung JY, and Reijo Pera RA (2009) Dazl functions in maintenance of pluripotency and genetic and epigenetic programs of differentiation in mouse primordial germ cells in vivo and in vitro. PLoS ONE 4, e5654.

43. Nicholas CR, Chavez SL, Baker VL, and Reijo Pera RA (2009) Instructing an embryonic stem cell-derived oocyte fate: lessons from endogenous oogenesis. Endocrine Reviews 30, 264-83.

44. RA Reijo Pera, DeJonge C, Bossert N, Yang JYH, Meneses J, Asadi N, Wong W, Wong C and Firpo MT (2009) Gene expression profiles of human inner cell mass cells and embryonic stem cells. Differentiation 78,18-23.

45. Nicholas CR, Banani SF, Xu EY, Hammer RE, Hamra FK, and Reijo Pera RA (2009) Characterization of a Dazl-GFP germ cell specific reporter. Genesis 47, 74-84.

46. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Reijo Pera RA, Lao K, and Clarke MF. (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603.

47. Kossack N, Meneses J, Shefi S, Nguyen H, Chavez S, Nicholas C, Gromoll J, Turek PJ, and Reijo Pera RA (2009) Isolation and charactrization of pluripotent human spermatogonial stem cell-derived cells. Stem Cells 27, 138-49.

48. K Foygel, B Choi, S Jun, DE Leong, A Lee, CC Wong, E Zuo, M Eckart, RA Reijo Pera, WH Wong, MWM Yao (2008) A novel and critical role for Oct4 as a regulator of the maternal-embryonic transition. PLoS One 3, e4109.

49. Walsh TJ, Reijo Pera RA, and Turek PJ (2008) The genetics of male infertility. Seminars in Reproductive Medicine 27, 124-36.

50. Scott CT and Reijo Pera RA (2009) The road to pluripotence: The research response to the embryonic stem cell debate. Human Molecular Genetics 17, R3-9.

51. Chavez SL, Meneses JJ, Nguyen HN, Kim S, and Reijo Pera RA (2008) Characteristics of six new human embryonic stem cell lines (HSF-7, -8, -9, -10, -12 and -13) derived with minimal animal product conditions. Stem Cells & Development 17, 535-546.

52. Sunny H, Choi JB, Shahine L, Westphal LM, Behr B, Reijo Pera RA, Wong WH and Yao MW (2008) Defining human embryo phenotypes by cohort-specific prognostic factors. PLoS One 3, e2562.

53. McElroy SL, Kee K, Tran N, Giudice LC, Meneses J and Reijo Pera RA (2008) Developmental competence of immature and abnormally-fertilized human oocytes in somatic cell nuclear transfer. Reproductive BioMedicine Online 16, 684-693.

8

54. Wong C, Gaspar-Maia A, Ramalho Santos M, and Reijo Pera RA (2008) High-efficiency stem cell fusion-mediated assay reveals Sall4 as an enhancer of reprogramming. PLoS One 3:e1955.

55. Kee K and Reijo Pera RA (2008) Human germ cell lineage differentiation from embryonic stem cells. CSH Protocols prot5048.

56. Nguyen HN and Reijo Pera RA (2008) Metaphase spreads and spectral karyotyping of human embryonic stem cells. CSH Protocols prot5047.

57. Angeles VT and Reijo Pera RA (2008) DNA methylation analysis of human imprinted Loci by bisulfite genomic sequencing. CSH Protocols prot5046.

58. Nicholas CR and Reijo Pera RA (2008) Method for single-cell sorting and expansion of genetically modified human embryonic stem cells. CSH Protocols prot5045.

59. McElroy SL and Reijo Pera RA (2008) Culturing human embryonic stem cells in feeder-free conditions. CSH Protocols prot5044.

60. Gallardo TD, John GB, Bradshaw K, Welt C, Reijo Pera RA, Vogt PH, Touraine P and Bione S, (2007) Toniolo D, Nelson LM, Zinn AR, Castrillon DH. Sequence variation at the human FOXO3 locus: a study of premature ovarian failure and primary amenorrhea. Human Reproduction 23:216-21.

61. International Stem Cell Initiative: International Stem Cell Initiative, Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B, Brooking J, Chen KG, Choo AB, Churchill GA, Corbel M, Damjanov I, Draper JS, Dvorak P, Emanuelsson K, Fleck RA, Ford A, Gertow K, Gertsenstein M, Gokhale PJ, Hamilton RS, Hampl A, Healy LE, Hovatta O, Hyllner J, Imreh MP, Itskovitz-Eldor J, Jackson J, Johnson JL, Jones M, Kee K, King BL, Knowles BB, Lako M, Lebrin F, Mallon BS, Manning D, Mayshar Y, McKay RD, Michalska AE, Mikkola M, Mileikovsky M, Minger SL, Moore HD, Mummery CL, Nagy A, Nakatsuji N, O'Brien CM, Oh SK, Olsson C, Otonkoski T, Park KY, Passier R, Patel H, Patel M, Pedersen R, Pera MF, Piekarczyk MS, Reijo Pera RA, Reubinoff BE, Robins AJ, Rossant J, Rugg-Gunn P, Schulz TC, Semb H, Sherrer ES, Siemen H, Stacey GN, Stojkovic M, Suemori H, Szatkiewicz J, Turetsky T, Tuuri T, van den Brink S, Vintersten K, Vuoristo S, Ward D, Weaver TA, Young LA and Zhang W. (2007) Characteristics of human embryonic stem cell lines: Results from the International Stem Cell Initiative. Nature Biotechnology 25, 803-16.

62. Angeles VT and Reijo Pera RA (2007) Differentiation of germ cells from embryonic stem cells. Chapter 7 in Human Embryonic Stem Cells. Edited by J Thomson, B Paulssen and J Masters; Springer-Verlag; New York, NY.

63. Haston KM and Reijo Pera RA (2007) Germ line determinants and oogenesis. Chapter 8 in Developmental Genetics. Edited by S Moody; Elsevier Press; New York, NY.

64. Fox MS, Clark AT, El Majdoubi M, Vigne JL, Urano J, Hostetler CE, Griswold MD, Weiner RI, and Reijo Pera RA (2007) Intermolecular interactions of homologs of germ plasm components in mammalian germ cells and embryonic stem cells. Developmental Biology 301, 417-431.

65. Nicholas C, Gaur M, Leavitt AD and Reijo Pera RA (2007) Generation of genetically-stable, GFP-positive human embryonic stem cell lines for long term transplantation studies. Stem Cells & Development 16:109-17.

66. Xu EY, Salmon NA, and Reijo Pera RA (2007) A gene trap mutation of a murine homolog of the Drosophila stem cell factor Pumilio results in smaller testes but does not affect litter size or fertility. Molecular Reproduction & Development 74, 912-21.

67. Clark AT and Reijo Pera RA (2006) Modeling human germ cell development with embryonic stem cells. Regenerative Medicine 1, 85-93.

68. Tung J, Rosen M, Cramer D, and Reijo Pera RA (2006) Common variants in Deleted in AZoospermia-Like (DAZL) are correlated with reproductive parameters in men and women. Human Genetics 118, 730-40.

9

69. Tung JY, Luetjens CM, Wistuba J, Xu EY, Reijo Pera RA, and Gromoll J (2006) Evolutionary comparison of the reproductive genes, DAZL and BOULE, in primates with and without DAZ. Developmental Genes & Evolution 216, 158-68.

70. Tung JY, Rosen MR, Turek PJ, Witte JS, Nelson L, Cramer D, Cedars MI and Reijo Pera RA (2006) Novel missense mutations of the Deleted-in-AZoospermia-Like (DAZL) gene in infertile women and men. Reproductive Biology & Endocrinology 4, 40.

71. Salmon NA, Reijo Pera RA, and Xu EY (2006) A gene trap knockout of the abundant sperm tail protein, outer dense fiber 2, results in preimplantation lethality. Genesis 44, 515-22.

72. Kee K, Gonsalves JM, Clark AT, and Reijo Pera RA (2006) Bone morphogenetic proteins induce germ cell differentiation from human embryonic stem cells. Stem Cells & Development 15, 831-7.

73. Fox MS, Reijo Pera RA and Clark AT (2006) “Chapter 12 : The DAZ gene family and human germ cell development from embryonic stem cells” in The Sperm Cell: Production, Maturation, Fertilization, Regeneration; C DeJonge, editor; Cambridge University Press, Cambridge, UK.

74. Lo B, Zettler P, Cedars MI, Gates E, Kriegstein AR, Oberman M, Reijo Pera RA, Wagner RM, Weurth MT, Wolf LE, Yamamoto KR (2005) A new era in the ethics of human embryonic stem cell research. Stem Cells 23, 1454-9.

75. Fox M, Urano J, Reijo Pera RA (2005) Identification and characterization of RNA sequences to which human PUMILIO-2 (PUM2) and Deleted in Azoospermia-like (DAZL) bind. Genomics 85, 92-105.

76. Urano J, Fox MS, and Reijo Pera RA (2005) Interaction of the conserved meiotic regulators, BOULE (BOL) and PUMILIO-2 (PUM2). Molecular Reproduction & Development 71, 290-8.

77. Gonsalves J, Turek PJ, Schlegel PN, Hopps CV, Fung Weier J and Reijo Pera RA (2005) Recombination in men with Klinefelter syndrome. Reproduction 130, 223-9.

78. Ezeh UI, Turek PJ, Reijo Pera RA and Clark AT (2005) Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-65.

79. Reijo Pera RA (2005) “Chapter 5: Genetics and Infertility” in Practical Pathways in Obstetrics and Gynecology – Infertility; Marcelle I. Cedars, Editor; McGraw Hill Company, NY, NY.

80. Looijenga LH, Hersmus R, Gillis AJ, Pfundt R, Stoop HJ, van Gurp RJ, Beltman J, Beverloo HB, van Drunen E, van Kessel AG, Reijo Pera RA, Schneider DT, Summersgill B, Shipley J, McIntyre A, van der Spek P, Schoenmakers E, and Oosterhuis JW (2005) Genomic and expression profiling of human spermatogcytic seminomas: Primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Research 66, 290-302. .

81. Clark AT, Rodriguez R, Abeyta MJ, Firpo MT, and Reijo Pera RA (2004) Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hot-spot for teratocarcinoma. Stem Cells 22, 169-79.

82. Moore FL, Jaruzelska J, Dorfman DM, and Reijo Pera RA (2004) Identification of a novel gene, DZIP (DAZ-Interacting Protein), that encodes a protein that interacts with DAZ (Deleted in AZoospermia) and is expressed in embryonic stem cells and germ cells. Genomics 83, 834-43.

83. Abeyta MJ, Clark AT, Rodriguez R, Reijo Pera RA and Firpo MT (2004) Unique gene expression signatures of independently-derived human embryonic stem cell lines. Human Molecular Genetics 13, 601-8.

84. Dobson AT, Raja R, Abeyta MJ, Taylor T, Shen S, Haqq C, and Reijo Pera RA (2004) The unique transcriptome through day 3 of human preimplantation development. Human Molecular Genetics 13, 1461-70.

10

85. Clark AT, Bodnar MS, Fox MS, Rodriquez RT, Abeyta MJ, Firpo MT, and Reijo Pera RA (2004) Spontaneous differentiation of germ cells from human embryonic stem cells in vitro. Human Molecular Genetics 13, 727-39.

86. Gonsalves J, Sun F, Schlegel PN, Turek PJ, Hopps CV, Green C, Martin RH and Reijo Pera RA (2004) Defective recombination in infertile men. Human Molecular Genetics 13, 2875-83.

87. Luetjens CM, Xu EY, Reijo Pera RA, Kamischke A, Nieschlag E, and Gromoll J (2004) Association of meiotic arrest with lack of BOULE protein expression in infertile men. Journal Clinical Endocrinology & Metabolism 89, 1926-33.

88. Fox MS, Ares VX, Turek PJ, Haqq C, and Reijo Pera RA (2003) Feasibility of global gene expression analysis in testicular biopsies from infertile men. Molecular Reproduction & Development 66, 403-21.

89. Moore FL, Jaruzelska J, Fox M, Urano J, Firpo MT, Turek PJ, Dorfman DM, and Reijo Pera RA (2003) Human Pumilio-2 is expressed in embryonic stem cells and germ cells and interacts with DAZ (Deleted in AZoospermia) and DAZ-Like proteins. Proceedings National Academy of Sciences 100, 538-43.

90. Jaruzelska J, Kotecki M, Kusz K, Spik A, Firpo M, and Reijo Pera RA (2003) Conservation of a Pumilio-Nanos complex from germ plasm to human germ cells. Developmental Genes & Evolution 213, 120-6.

91. Xu EY, Lee DF, Klebes A, Kornberg T, Turek PJ, and Reijo Pera RA (2003) Human BOULE rescues meiotic defects in infertile flies. Human Molecular Genetics 12, 169-75.

92. Hubbard EJA and Reijo Pera RA (2003) Starring roles in “A germ cell odyssey: Survival, migration, stem cells and differentiation.” European Molecular Biology Organization (EMBO) Reports 4, 352-7.

93. Feng LX, Chen Y, Dettin L, Hofmann MC, Reijo Pera RA, Herr JC, Goldberg E, and Dym M (2002) Generation and in vitro differentiation of a spermatogonial cell line. Science 297, 392-5.

94. Turek PJ and Reijo Pera RA (2002) Current and future genetic screening for male infertility. Urological Clinics of North America 29,767-92.

95. Fox MS and Reijo Pera RA (2001) Male infertility, genetic analysis of the DAZ genes on the human Y chromosome and genetic analysis of DNA repair. Molecular and Cellular Endocrinology 184, 41-9.

96. Turek PJ and Reijo Pera RA (2001) “Fertility and Mutations” in The Encyclopedia of Genetics; Lee Silver, Editor; Academic Press, NY.

97. Xu EY, Moore FL, and Reijo Pera RA (2001) A gene family required for human germ cell development evolved from an ancient meiotic gene conserved in metazoans. Proceedings National Academy of Sciences 98, 7414-9.

98. Meng MV, Black LD, Cha I, Ljung B-M, Reijo Pera RA, and Turek PJ (2001) Impaired spermatogenesis in men with congenital absence of the vas deferens. Human Reproduction 16, 529-33.

99. Cayan S, Lee DM, Black LD, Reijo Pera RA, and Turek PJ (2001) Response to varicocelectomy in oligospermic infertile men with and without coexisting genetic infertility. Urology 57, 530-5.

100. Moore FL and Reijo Pera RA (2000) Male sperm motility dictated by Mother’s mtDNA. American Journal of Human Genetics 67, 543-8.

101. Reijo Pera RA (2000) "The DAZ genes and early germ cell development" in The Testis: From Stem Cell to Sperm Function, E. Goldberg, Ed., Springer -Verlag Publishing, NY, NY. pp. 213-25.

102. Reijo RA, Dorfman D, Renshaw A, Loughlin K, Page DC (2000) DAZ and DAZL proteins: candidate human fertility factors expressed in prenatal and postnatal germ cells transit from the nucleus to cytoplasm at meiosis. Biology of Reproduction 63, 1490-96.

11

103. Nudell D, Castillo M, Turek PJ, and Reijo Pera, RA (2000) Defective DNA repair in infertile men. Human Reproduction15, 1289-94.

104. Moore FL and Reijo Pera RA (2000) Male sperm motility dictated by Mother’s mtDNA. American Journal Human Genetics 67, 543-8.

105. Dorfman D, Genest D, and Reijo Pera RA (1999) Human DAZL1 encodes a candidate fertility factor in women that localizes to the prenatal and postnatal germ cells. Human Reproduction 14, 2531-36.

106. Kostiner DR, PJ Turek, and Reijo Pera RA (1998) Male infertility: analysis of the markers and genes on the human Y chromosome. Human Reproduction 13, 3032-8.

107. Mulhall, JP, Reijo RA, Alaggappan R, Brown L, Page DC, Carson R, and Oates RD (1997) Azoospermic men with deletion of the DAZ genes are capable of completing spermatogenesis: fertilization, normal embryonic development and pregnancy occur when retrieved testicular spermatozoa are used for intracytoplasmic sperm injection. Human Reproduction 12, 503-8.

108. Reijo RA, Seligman J, Dinulos MB, Jaffe T, Disteche CM, and Page DC (1996). Mouse autosomal homolog of DAZ, a candidate male sterility gene in humans expressed in male germs cells before and after puberty. Genomics 35, 346-52.

109. Reijo R, Alagappan R, Patrizio P, Page DC (1996). Severe oligospermia resulting from deletions of the Azoospermia Factor gene on the Y chromosome. Lancet 347, 1290-3.

110. Saxena R, Brown LG, Hawkins T, Alagappan RK, Skaletsky H, Reeve MP, Reijo RA, Rozen S, Dinulos MB, Disteche CM, Page DC (1996) The DAZ gene cluster on the human Y chromosome arose from an autosomal gene that was transposed, repeatedly amplified and pruned. Nature Genetics 14, 292-9.

111. Tsuchiya K, Reijo RA, Page DC, Disteche CM (1995) Gonadoblastoma: Molecular definition of the susceptibility region on the Y Chromosome. American Journal Human Genetics 57, 1400-7.

112. Reijo R, Lee TY, Salo P, Alagappan R, Brown LG, Rosenberg M, Rozen S, Jaffe T, Straus, D, Hovatta O, de la Chapelle A, Silber S, Page DC (1995) Diverse spermatogenic defects in humans caused by overlapping, de novo Y deletions encompassing a novel RNA-binding protein gene. Nature Genetics 10, 383-93.

113. Reijo RA, Cooper EM, Beagle GJ, Huffaker TC (1994) Systematic mutational analysis of the yeast beta-tubulin gene. Molecular Biology of the Cell 5, 29-43.

114. Reijo RA, Cho DS, Huffaker TC (1993) Deletion of a single-copy tRNA affects microtubule function in Saccharomyces cerevisiae. Genetics 135, 955-62.

115. Krueger (Reijo) RA, Broce AB, Hopkins TL, Kramer KJ (1988) Calcium transport from Malpighian tubules to puparial cuticle of Musca autumnalis. Journal Comparative Physiology B: Biochemical, Systemic, and Environmental 158, 413-9.

ACTIVE GRANTS

Grant 11371396 (Reijo Pera, Renee, Principle Investigator (PI)) 5% effort 2013-NIST-MSE-01: Measurement Science and Engineering (MSE) Research Grant Programs National Institutes of Standards and Technology (NIST) 09/01/2013 – 08/31/2016 $255,000/year direct ($1.2M total) Stanford University Advances in Biological Measurement Sciences Program (ABMS) This award serves as the founding grant culminating more than 5 years of program building to seed a joint Stanford:NIST Center of Excellence aimed at providing quantitative methods for measurement science in biology. 1 U54 DH068158-01 (Reijo Pera, Renee, Principle Investigator (PI)) 21% effort 04/01/2011-03/31/2016

12

National Institutes of Health (NICHD) $1,084,640/year direct ($8.6M total) Stanford University Center for Reproductive and Stem Cell Biology This award established the formal Center for Reproductive and Stem Cell Biology at Stanford with major goals to translate basic knowledge of reproductive biology in flies and mice to clinical applications in infertility. Dr Reijo Pera directs the Center comprised of 6 primary faculty and 6 associate members, lab scientists, graduate and postgraduate students.

5 U01 HL100397-03 (Cooke, John P, PI) 8% effort 09/30/2009-04/30/2016 National Institutes of Health $758,459/year direct ($5.7M total) Basic and translational research iPSC-based hematologic and vascular therapies The main goals of this project are 1) To develop and refine reagents and protocols for an NCE-based strategy of generating hiPSCs, 2) To characterize the safety and function of these hiPSCs. Role- coPI (multiple PI with J Cooke)

5 R01 HL097516-03 (Yang, Phillip C, PI) 09/01/2009 - 06/30/2013 (NCX 06/30/2014) National Institutes of Health $23,000 (salary only; $115,000 total) Comprehensive In Vivo MRI of Mouse Embryonic Stem Cell Myocardial Engraftment Examine mESC/hESC differentiation to cardiac precursors and engraftment in mouse models. Role- Co-Investigator

1RC1HD06347901 (Reijo Pera, Renee, PI) 9% effort 07/19/2010-NCX 09/30/2013) National Institutes of Health $312,311/year direct ($1.7M total) Oocyte factors for reprogramming to pluripotency The aims of this project are 1) Profile gene expression in individual mouse and human oocytes before and after treatment with luteinizing hormone (LH), 2) monitor oocyte development to blastocyst stage following genetic manipulations to suppress or increase the expression of key oocyte genes that we identify upregulated during cytoplasmic maturation, 3) reprogram somatic cells from our RENEW BioBank with “traditional factors” plus/minus our candidate enhancers.

Stanford SCORE Grant Reijo Pera, Renee, PI) 2012-completion $8634 total Development of curriculum for Human Development course The goal of this award is to develop new curriculum for STEMREM201, a human developmental biology course.

6FY10351 (Reijo Pera, Renee, PI) 5% effort 06/01/2010-05/31/2013 (NCX 05/31/2014) March of Dimes Birth Defects Foundation $91,928/year direct ($330,000 total) Molecular genetic analysis of human imprinting and assisted reproduction The major goal of this program is to examine risks associated with the use of assisted reproduction in terms of imprinting and genetic instability

T1-00001 (Renee A. Reijo Pera, Director) 2% effort 06/01/12 to 5/31/15 • California Institute for Regenerative Medicine $3.7M total • Stanford Scholar Training Program The major goal of this project is to educate the next generation of cholars at Stanford to support the training of 10 predoctoral, 4 postdoctoral and 2 clinical fellows in the basic biology, translational and clinical use of pluripotent and adult stem cells.

CL10051801 (Reijo Pera, Renee, PI) 4% effort 09/01/2007-08/31/2014 California Institute for Regenerative Medicine $400,000/year direct ($5.8M total) Stanford Shared Research Lab & Stem Cell Techniques Course The major goal of this project is to establish a premiere center for human embryonic stem cell research and education at Stanford University

Reijo Pera (PI) (Reijo Pera, Renee, PI) 06/01/2009-5/31/2015 San Jose State University $43,250/year Effort as needed ($129,000 total) San Jose State University Stem Cell Internships in Lab-Based Learning (SJSU SCILL)

13

The primary goal of this project is to support interns (BS and MS-degree candidates) from the CSU (California State University) system, especially those of diverse backgrounds, with salary and supplies while studying at Stanford University.

Reijo Pera (PI) (Reijo Pera, Renee, PI) 07/01/2009–6/30/2015 Humboldt State University $17,250/year ($50K total) Effort as needed The HSU CIRM Bridges to Stem Cell Research Certificate Program The primary goal of this project is to support interns from the CSU (California State University) system, especially those of diverse backgrounds, with salary and supplies while studying at Stanford University.

RB3-02209 (Reijo Pera, Renee - PI) 25% effort 09/01/2011-05/31/2014 California Institute for Regenerative Medicine $300,000/year direct ($1.4M total) Correlated time-lapse imaging and single cell analysis of human embryo-development The major goals are to use knowledge of human embryo development to improve clinical applications in both reproductive and regenerative medicine and inform our understanding and practices in human pluripotent stem cell biology.

RB2-01553 (Hsueh, Aaron J W, PI) 08/01/2010-07/31/2013 California Institute for Regenerative Medicine $300,000/year ($1.7M total) Maturation of Human Oocytes The major goals are to refine methods to mature human oocytes from primary tissue for applications that allow treatments for women with cancer and ovarian failure and improvements in derivation of stem cell lines.

TR3-05569 (Reijo Pera, Renee, PI) 10/1/2012– 9/2015 California Institute for Regenerative Medicine $1.2M/year direct ($5.3M total) Autologous iPSC Therapy and Women’s Health The major goals of this research are to develop non-invasive imaging methods and algorithms to predict stem cell fate of reprogrammed adult stem cells, differentiated to smooth muscle, for use to alleviate common problems of women’s health with the first treatment targeted to urinary incontinence.

CIRM RB4-06087 (Brunet (PI); Reijo Pera, Renee, Co-PI) 05/01/13-4/30/16 California Institute for Regenerative Medicine $48,829/year direct (146,487 total) Energy Metabolism and aging pathways in human stem cell reprogramming and differentiation The main goal of this project is to use iPSCs to probe alterations in energy metabolism with aging.

MAJOR PRIVATE DONATIONS John and Jill Freidenrich, Stanford Alumni and Regis Management Company, LLC (2011-present)

Lenore and Dale Meyer (2012 – present)

Duane and Marlene Dunwoodie Fund for Parkinson’s Disease Research (2008-present)

Anonymous Donor (2007-present)

Stanford Photonics Research Center Combined Imaging Program with St Andrews University, Scotland (2009)

Family of John Boothryd, San Jose State University (2010)

Herbert and Marion Sandler, Golden West Financial Corporation (1998-2004)

PAST GRANTS Reijo Pera (PI) (Reijo Pera, Renee, PI Subcontract) 4% 08/01/2009–7/31/2012 Parkinson’s Institute (Prime sponsor-CIRM)

14

Using patient-specific IPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery Goal was to derive iPSCs from patients with Parkinson’s Disease in order to examine fundamental disease characteristics and response of dopaminergic neurons to environmental/pharmaceutical agents.

RC1-00137-1 (Renee A. Reijo Pera, PI) 07/01/07 to 06/30/11 • California Institute for Regenerative Medicine • Human Oocyte Development and Reprogramming The major goal of this project was to differentiate multiple hESC lines to germ line derivatives in order to characterize the developmental program of human reprogramming, as it is executed by cells of the human germ cell lineage.

U54HD055764 (Renee A. Reijo Pera, Project I, PI) 03/01/07 to 2/28/12 • National Institute of Child Health and Human Development • Differentiation of Human Germ Cells The major goal of this project is to examine the hypothesis that common deletions and polymorphisms in humans impact germ cell development.

R01 HD047721-01 (Renee A. Reijo Pera, PI) 7/01/05 to 6/30/10 • National Institute of Child Health and Human Development • Genetic Analysis of Human Germ Cell Formation The major aims of this grant are to: 1) Characterize the ability of male germ cells to differentiate from human ES cells, 2) silence Y chromosome genes implicated in male germ cell development and assess development in vitro and 3) silence Y chromosome genes implicated in male germ cell development and assess development in vivo in a primate transplant system.

RO1 44876 (Marcelle I. Cedars, PI) 01/01/05 to 12/31/09 • National Institute of Aging NIH 1 RO1 44876 Renee Reijo Pera, Co-PI • Genetic Epidemiology of Ovarian Aging The major goal of this project is to explore the hypothesis that ovarian aging, as reflected by antral follicle count (a reflection of oocyte number), is largely determined by genetic polymorphisms (in genes such as DAZL and Interacting Genes) that impact initial oocyte endowment and rate of oocyte loss over time.

14RT-0159 (Renee A. Reijo Pera, PI) 6/01/05 to 05/31/08 • Tobacco Related Disease Research Progam (California) • Human Oocyte Development and PAH Exposure The major goal of this program is to differentiate human oocytes from hESCs in the presence and absence of PAH (polycyclic aromatic hydrocarbons) to assess effects of exposure to chemicals commonly found in secondhand smoke.

NIH 2 R24 RR017498 (Renee A. Reijo Pera, PI) 07/01/05 to 6/30/07 • National Center for Research Resources • Federally Registered Human Embryonic Stem Cell Center The major goals of this project are to: 1) Distribute federally-approved human embryonic stem cell lines, HSF-6 and HSF-1 and 2) establish a training program in human embryonic stem cell culture.

NIH R01HD37095 (Renee A. Reijo Pera, PI) 07/01/99 to 6/30/05 • The DAZ genes and early germ cell development in humans The major goal of this project is to determine how the DAZ gene family functions in allocation (formation) of germ line stem cells in men and women. Searle Scholar Award (Renee A. Reijo, P.I.) 7/1/98 to 6/30/01

15

Genetic and molecular strategies for identification of factors required for allocation and totipotency of human germ cell lineage The goals of this research included identification of proteins and RNAs that interact with the DAZ gene family, identification of other genes necessary for germ cell allocation to occur and to determine what phenotypes are associated with mutations in the DAZ gene family.

UC System (Renee A. Reijo, PI) 10/1/98 to 12/31/00 • University of California Campus-Laboratory Collaboration • Use of cDNA microarrays to identify and characterize quantitative and qualitative defects in expression of fertility genes in infertile men The goals of this project included the identification of genes that map to autosomes or sex chromosomes that are necessary for men to make sperm, exploring the function of each gene by using cDNA microarrays and to determine the order of function of each gene and mutations which disrupt their function.

UCSF (Renee A. Reijo, PI) 11/1/98 to 10/31/99 • UCSF Chancellor’s Award in Basic Science • Meiotic arrest and defects in the recombination and DNA repair pathways in infertile men The goal of this project was to compare sperm from infertile men with meiotic arrest with that of fertile men in two ways: the percent of recombination and the fidelity of DNA repair in each group of men

RO1 ES 08750 (Renee A. Reijo, PI) 10/1/01 to 9/30/02 • National Institutes of Health (Environmental Sciences) • Cellular and Molecular Response to DNA Repair Deficiency • This project was transferred to Dr. Reijo by Dr. Pedersen in order to allow completion of research begun by Roger A. Pedersen, Ph.D. The goal of this project was to understand the role of the XRCC1 in modulating damaging effects of various mutagens, particularly DNA damage induced by exposure to radiation or radio-mimetic chemicals, in the germ cells and embryo.

California Urology Association (Renee A. Reijo and Paul J. Turek, Co-PIs) 7/01/01 to 6/30/02 Gene Expression Patterns in Laser-Captured Germ Cell Populations The overall goal of the proposed research is to elucidate gene expression in particular germ cell populations, especially the germ stem cells.

UCSF (Renee A. Reijo Pera, PI) 9/01/03 to 8/31/04 • UCSF Developmental and Stem Cell Biology Award • Molecular Exploration of New Candidate Pluripotency Factors, GDF3, STELLA and NSTEL in Humans and Mice The major goals of this project were to characterize genes, GDF3, STELLA and NANOG by overexpressing and silencing the genes in human embryonic stem cells.

1 RO1 HD38987 (Renee A. Reijo Pera, PI) 4/01/01 to 3/31/07 • NIH 1 RO1 HD38987 • Genetic Analysis of Meiosis in Men and Risks Associated with ICSI The major goals of this project are to determine if defects in DNA repair and recombination cause infertility in men, to identify and characterize genes that cause meiotic arrest in men, and to assess genetic risks in children conceived via intracytoplasmic sperm injection from sperm obtained from men with meiotic arrest.

ACTRF (Renee A. Reijo Pera, PI) 04/01/04 to 8/31/06 • American Cell Therapy Research Foundation • Imprinting and human ES Cell-Derived Germ Cells

16

The major goals of this project are to: 1) Optimize differentiation of human germ cells of each sex in vitro and 2) examine sex-specific imprinting in differentiated germ cells.

UCSF (Renee A. Reijo Pera, PI) 01/01/05 to 12/31/08 • UCSF School of Medicine • Establishment of the UCSF Program in Human Embryonic Stem Cell Biology The major goal of this project is to establish the UCSF Human Embryonic Stem Cell Research Center that possesses the personnel and scientific tools to develop models of human development based on pluripotent stem cells. Ten highlights of research accomplishments 1) Identification of the highly-conserved gene family, Deleted in AZoospermia (DAZ), as the

most common molecularly-defined cause of human infertility and homologs in all animals 2) Identification of germ plasm proteins that interact with with DAZ family members in the

human germ line and have homologs broadly in other species 3) Identification of novel genetic variants associated with age of onset of menopause and other

reproductive parameters in women and men 4) First complete transcriptome analysis of the human oocyte to egg transition and

demonstration that the clock that regulates embryonic genome activation is independent of cell cycles

5) Development of a model to study human germ cell development from female and male primordial germ cells to initiation and progression in meiosis

6) Genetic modulation of germ cell genes to increase/decrease human germ cell formation in vitro

7) First non-invasive correlated time-lapse imaging and molecular model of human embryo development to minimize adverse outcomes in assisted reproduction including embryo loss, miscarriage and multiple births

9) First “disease-in-a-dish” from Parkinson’s patient pluripotent stem cells 10) First non-invasive diagnosis of chromosomal abnormalities in human cells via imaging SUMMARY of RESEARCH DIRECTIONS

Current research efforts are focused on three areas of human development and disease: A. Human Development: The Segregation of Somatic and Germ Cell Lineages I am classically trained as a geneticist and have spent many years in the last decade focused on translating studies from flies, worms, mice and frogs to human development. We have seen great advances in human biology that may now allow us to overcome two historically-significant limitations in human developmental genetic studies: The inaccessibility of early human development to biological experimentation and the genetic-intractability of the human genome during development. More than a decade and a half ago, we identified a gene family required for germ cell formation/maintenance of initial populations; subsequently, we developed a testable model for germ cell formation, and differentiated germ cells from human embryonic and induced pluripotent stem cells in order to probe the genetics of human germ cell formation and dependence on key genes that we have shown are deleted, mutated or variant in men and women with few or no germ cells. A major focus of our laboratory is to define the baseline molecular, temporal and genetic characteristics of differentiation of hESCs, iPSCs and mESCs to the germ cell lineage in vitro and in vivo in a xenograft transplant system. For this purpose, we have developed induced pluripotent stem cell (iPSC) lines that carry deletions of the Y chromosome that encompass three loci and have assessed germ cell development and are reconstructing the pathways via complementation analysis (with TALENs) and via cell lineage tracking in vivo. We have received venture funding to extend studies to clinical applications in human reproduction for fertility preservation and restoration. Studies are applicable to model

17

systems as well.

B. Constructing a Web-based Map of Human Embryo Development Over the last several years, we have collaborated with computer scientists, applied physicists, bioethicists and others to begin to construct an atlas of human embryo development with the goal of defining the molecular, genetic, epigenetic and imaging pathways that determine success and failure of development in vitro and in hESC and iPSC models. We began by examining the development of a large set of normally-fertilized one-cell embryos and found that success in human development to the blastocyst stage could be predicted with >93% sensitivity and specificity by measuring three dynamic, noninvasive time-lapse cell cycle imaging parameters by day 2 of development, prior to embryonic genome activation (EGA). These parameters can be reliably modeled and monitored by automated image analysis and reflect underlying molecular programs (molecular health) indicative of individual blastomeres. Further, single-cell gene expression analysis revealed that individual blastomeres within the embryo develop cell autonomously by the 8-cell stage and are characterized by distinct gene expression diagnostic of reprogramming. These studies formed the foundation to examine dynamics and chromosome composition (ploidy) as described by Chavez et al (Nature Comm, 2013). We are now examining the molecular clocks that may function in timing of the human embryonic genome and determining the relationship between predictive imaging parameters and epigenetic disturbance, while also extending findings to human pluripotent stem cells. In the next three years, I would seek to collaborate with computer scientists, those in the humanities and arts, and engineering communities to complete a web-based map of human development based on data already generated in our studies and world-wide.

C. Understanding Parkinson’s Disease. Historically, studies of human disease, including Parkinson’s disease (PD), have been hindered by lack of access to affected human dopaminergic (DA) neurons. We generated multiple iPSC lines with PD with and without genetically-defined mutations and examined their characteristics in detail. The first complete analysis that we accomplished was of cell lines from a 60-year old woman, and her son, who carry the p.G2019S mutation (G2019S-iPSCs) in the Leucine-Rich Repeat Kinase-2 (LRRK2) gene, the most common PD-related mutation. The LRRK2 mutation was a natural starting place for analysis as it is highly-penetrant, common, and bears strong resemblance to sporadic PD suggesting that these cells could provide a valuable platform for broad applications in understanding the disease and developing pharmaceutical interventions. We found that DA neurons derived from G2019S-iPSCs showed increased expression of key oxidative stress-response genes and alpha-synuclein protein. The mutant neurons were also more sensitive to environmental toxins as indicated by caspase-3 activation and cell death caused by exposure to stress agents. Overall, the enhanced stress sensitivity combined with protein aggregation is consistent with early PD phenotypes. Moreover, these lines from affected and control individuals provide the necessary biological materials for exploration of the formation of Lewy-body structures in response to stress and allow us to address: 1) Ontogeny, 2) composition and quantity, and 3) potential modifying strategies.

D. Human Pluripotent Stem Cells as the Preeminent Model for Human Developmental Genetics and a University-Wide Shared Laboratory Facility In 2003, I proposed that UCSF should establish a formal human embryonic stem cell program; we received R24 NIH funding for those efforts. The program was aimed at developing new tools to probe the fundamentals of human developmental genetics. Clearly, human genetics has sometimes suffered from the lack of a rigorous system to experimentally manipulate human genes of interest through development and likewise, human stem cell and developmental biology has often suffered from lack of genetic rigor in its early stages. Thus, the overall goal was to establish a combined program of human genetics and stem cell biology that allows the use of stem cells to address human genetic questions, and vice versa. We expanded these

18

efforts at both UCSF and Stanford and have generated many of the tools necessary to probe fundamentals of somatic and germ line development for basic science and potential clinical applications, which are being realized. Our efforts in this arena are growing and are now a joint effort between the Department of Genetics and the Institute for Stem Cell Biology and Regenerative Medicine. SUMMARY of EDUCATIONAL ACCOMPLISHMENTS

I. Established the first new graduate program in the Stanford University School of Medicine in almost 30 years

The Stanford University interdepartmental graduate program in Stem Cell Biology and Regenerative Medicine was approved April 28, 2011. The approval represented 4 years of effort on my part through a process of building consensus where little consensus was present at the onset. This is the first new doctoral program in the Stanford School of Medicine in almost 30 years. This program was formed to provide a different model for doctoral study and offers abundant opportunities to work with faculty in the Institute for Stem Cell Biology and Regenerative Medicine and others in the surrounding Schools of Humanities and Sciences, Medicine, Law, Business, Earth Sciences and Engineering. Our goal is to provide students with an immersion in the very best basic science and to translate findings to applications – in essence enable change hopefully in the short-term and the long-term in the health of men, women and children in the arena of regenerative medicine. We hope to provide the optimal environment for success through a combination of didactic and laboratory-based courses in basic science and medicine with abundant opportunities in law, mathematics/statistics, chemistry, pharmaceutical sciences, business and engineering.

These are very exciting times for a different program, focused on the success of our students in a new venture in the heart of California’s Silicon Valley. Our program admitted the first class in Autumn of 2012. Our deadline for applications was December 1, 2011. We received almost 100 applications for 6 positions; we offered 12 students admission under standard assumptions of a 50% matriculation but had an acceptance rate of 90%. Our incoming class for 2013 was selected from almost 110 applications and 6 of 7 accepted. Our applicants arrive from around the world with individual diversity in terms of education including engineering, bioengineering, the biological and physical sciences, as well as diversity of background (socio-economic disadvantage and under-represented minorities (Native American and Hispanic). The applicants are competitive for programs across the country but demonstrated a commitment to applied science; several have spent time in reflecting on health care needs including research on leprosy in India, research on Parkinson’s Disease and Lou Gehrig’s disease, as well as on substrate chemistry and properties, applications in business and bioengineering.

II. Established inter-university educational internships between Stanford University and the California State University (CSU) system (Humboldt State University, San Francisco State University, San Jose State University, California State University Fullerton) and Pasadena City College. In 2009, we initiated the first Stanford internship program designed to provide research opportunities to students of the California State system. This program was begun under my direction, and aims to reach out into the community and attract students of diverse backgrounds. The internships are intense, lasting 12 months, and have been populated by excellent students who have taken full advantage of the opportunities; the students generally have just finished their Bachelor’s degree or are beginning Master’s degree-level education at their home institutions. The program begins with a one-week “boot-camp” or intensive on human development, genetics, epigenetics, stem cells and regenerative medicine in the shared laboratory facility. The students then disperse to the laboratories where they will conduct one year of research; they meet with me on a monthly basis, have mentors and co-mentors and

19

form a very tight-knit collaborative group among themselves (each year we have between 10-20 interns making this the largest intern program at Stanford for the longest duration of internship (a year rather than weeks or months)). The students have gone on to doctoral and medical education, government and policy positions, business, ad technical positions in industry.

III. Continued Efforts in Formal (Classroom) Teaching Here I describe my educational activities, first at UCSF and then at Stanford University. Please note that I relocated, with my laboratory, to Stanford University in April of 2007. At UCSF, I was an instructor in four courses and course director and instructor for a fifth course. I also directed the UCSF CIRM Stem Cell Training Program and was the principal investigator of an NIH-sponsored training and distribution program for federally-approved human embryonic stem cells. More details regarding these activities are described below: The courses in which I have instructed are: Medical Genetics (Pediatrics 100; 1998, 1999 and 2001), Genetics 200A (1999, 2000, 2001 and 2002), Advanced Human Genetics (1999), and Principles of Genetics (BMS255; 2003); I was course director and instructor in Biology of Human Tissues and Organ Systems (BMS 225A; 2004 – present), a course that I reorganized and renamed to “Developmental and Stem Cell Biology.” I have also established curriculum components at Stanford University since 2007 (as outlined further below). The Medical Genetics course was attended by medical students, Genetics 200A was attended by first-year graduate students in the Program in Biological Sciences (PIBS) and BioMedical Sciences (BMS), and Advanced Human Genetics was attended by advanced graduate students and postdoctoral fellows. In each of these courses, I taught linkage analysis, imprinting, pedigree analysis, gene mapping, gene identification strategies in humans, the Human Genome Project, and sex determination. As Course Director of BMS225A at UCSF, I reorganized the course content from basic physiology to a focus on Reproductive, Developmental and Stem Cell Biology. The overall goal of this course was to teach the students the basics of human development with a focus on embryology, stem cell biology and differentiation, and the basic development and function of somatic systems such as the cardiovascular system. In parallel, I organized a series of discussion sections that focused on (i) the histology of the individual tissues and organs and (ii) the critical analysis of recent papers exploring human biology and animal transgenic models to illustrate the concepts put forth in the lectures. In addition, there was a set of basic laboratory experiments demonstrating mouse/chick embryo dissection, embryology and human embryonic stem cell growth, differentiation and genetic analysis. Because of demand, the number of discussion groups and laboratories was increased, beginning with winter session (2005-2006). We included genetic modification and directed differentiation of pluripotent stem cells, as well. As Director of the Stanford CIRM training program, succeeding M Longaker, we require scholars to attend Developmental and Stem Cell Biology (syllabus below), a monthly course on ethical, legal and social issues related to stem cell biology, a translational biology course, and a two week course (which I designed to be offered 4 times annually) that includes a morning lecture and discussion and an afternoon of hands-on experience. As Director of the Stanford University CIRM Training Program and the Stem Cell Research and Education committee of the Institute for Stem Cell Biology & Regenerative Medicine, we offer our full menu of courses in stem cell biology, development and translation to the clinic to a diverse community of undergraduates, graduate students, postdoctoral fellows and clinical fellows. As Director of the Stanford University Center for Human Embryonic Stem Cell Research and Education, I direct a curriculum that has three components. Our entry level course is held six times annually; advanced courses concentrate on reprogramming of adult somatic cells to pluripotent stem cells, differentiation of cardiovascular derivations, and finally we have courses on imaging, single cell analysis and specialized techniques.

III. Development of a new curriculum on human development and disease including STEMREM201, STEMREM 202 (formally 296, see attached), and STEMREM203 (see attached

20

curriculum descriptions). Our goal is to provide the best educational opportunities possible to understand human development and disease, drawing on genetics, stem cell biology, developmental biology, cell biology, bioengineering, neuroscience, bioethics and related fields. Our courses are described below.

22

Stem Cell Biology and Regenerative Medicine 296 (now STEMREM202)

23

STEMREM203. This course could also be termed “Applications in Business, Law, Engineering, Humanities and/or Medicine.” STEMREM 203 provides the clinical, pharmaceutical, biotechnology or business immersion necessary to allow insight into the world of medicine from multiple vantage points, setting the stage, we hope for the students to translate research successfully beyond the academic sphere and gain the necessary knowledge, if possible, to move forward with their career goals and/or their research proposal/business plan as developed from their interests in STEMREM201 and STEMREM 202. As director, I facilitate the opportunities the students will explore via contacts in other schools/colleges, departments, Institutes and in the business community surrounding the university and abroad. We have opportunities at five companies, diverse departments across Stanford, at a government agency and in the venture community.

Other Teaching

Graduate Students: I currently have five doctoral graduate students and a large group of other graduate students who previously graduated from my laboratory (see attached). These students are obtaining, or have already obtained, degrees in Genetics, Cancer Biology, BioMedical Sciences, BioEngineering, Electrical Engineering and Mechanical Engineering but conduct their doctoral research completely in my laboratory. Each of these students has centered their thesis projects on human reproduction, adult and embryonic stem cell biology, induced pluripotent stem cells and/or genetic analysis.

Undergraduates: Undergraduates are a source of energy and inspiration in our laboratory. We have two year-round graduate students from Stanford University, and also host undergraduate students in my laboratory each summer (3-4 additional students), primarily from Stanford University, San Jose State University, Francisco State University and the University of California at Berkeley. We have, however, also hosted students from the University of Oregon, the University of Wisconsin, Princeton University, Ohio Northern University and others.

Postdoctoral Fellows: I have ten postdoctoral fellows currently; they have joined my laboratory after finishing doctoral work in diverse fields generally within the United States but also from Italy, Germany, China, Spain and Mexico. To date, my fellows have succeeded in both academic and private venues with positions at Genentech, Auxogyn, Inc., and Molecular Devices Corporation, as well as in academia (UCLA, UCSF, University of Valencia (Spain), Northwestern University and Tsinghua University (Beijing).

Medical Fellows/Residents/Mentorships: I have trained or am currently training many Medical fellows in my laboratory primarily from Medicine, Genetics, Ob-Gyn and Urology (10 fellows total). I also host international medical fellows on occasion primarily from Asia, Europe, and South America/Mexico.

CIRM Trainees: I currently am Director of the Stanford CIRM training program which combines stem cell biology, bioengineering and developmental biology into a coherent curriculum and research training plan. At UCSF, I also served as Founding Director of the UCSF CIRM training. I direct and coordinate formal education, consult on laboratory research, and arrange seminars and other educational venues for scholars.

High School Students: Each year, I host 2 – 3 high school students from the San Francisco and Silicon Valley public school systems through the High School Summer Internship Program through SEP (Science and Health Education Partnership. These students generally work with graduate and postdoctoral scholars in my laboratory but meet with me in joint meetings with the graduate students for 30 minutes/week.

Other: Staff Research Associates, interns, high school teachers, and visiting faculty are regular members of my laboratory over the years.

27

SELECTED PRESENTATIONS

International Medical Research Council (MRC); Edinborough, Scotland; September 1998 American Society of Reproductive Medicine (ASRM); Toronto, Ontario; September 1999 International Andrology Society; L' Aquila, Italy; March 2000 South American Infertility and Sterility Conference; Santiago, Chile; November 2000 European Society for Human Reproduction and Embryology, Vienna; June 2002 3rd European Congress of Andrology, Munster, Germany, September 2004 Swedish American Stem Cell Meeting: April 2005 International Society for Stem Cell Research: June 2005 UCSF and IMSUT (Institute of Medical Sciences, University of Tokyo) Joint Meeting; July 2005; Tokyo, Japan Seoul National University; October 2005 Valencia International Stem Cell Conference; March 2006 University of Finland, Tampere; Tissue Engineering Conference; May 2006 CIRM (California Institute for Regenerative Medicine):United Kingdom Stem Cell Workshop; November 2006 Bureau International des Poids et Mesures, “Measurements in Human Development”; Paris, France; June 2010 Kyoto University; June 2010 Australian Society for Reproductive Biology; October 2010 Hong Kong University; May 2009 Idea City: “Male growth and development;” Toronto, ON Canada September 2010 European Societyy for Human Reproduction and Embryology, Rome, Italy; July 2010 Latin American Reproductive Society Meeting; Rio De Janeiro, Brazil; May 2011 Tsinghua University; April 2011 European Societyy for Human Reproduction and Embryology, Stockholm, Sweden; July 2011 European Societyy for Human Reproduction and Embryology, Istanbul, Turkey; July 2012 National American Society of Andrology; Louisville, Kentucky; April 1999 Searle Scholars Meeting; April 1998; April 1999 Gordon Research Conference On Reproductive Tract Biology; Connecticut College; July 2000 Instructor, Woods Hole Marine Laboratory, Woods Hole, MA; “Reproductive Biology Course;”

June 2000, June 2009, 2010, 2011 American Society of Andrology – Testis Workshop; Seattle, WA; April 2002 Jackson Laboratory - Mouse Initiative IV: Complex Human Disease and Mouse Models; July

2002 Cold Spring Harbor Symposium, “Germ Cells;” October 2002 Endocrinology Division Grand Rounds, National Institutes of Health, January 2003. NIH Celebration of the 50th Anniversary of the NICHD, June 2003 American Society of Andrology – Baltimore, MD; April 2004 Keynote Address: Pacific Coast Reproductive Society, May 2004 Cold Spring Harbor Symposium, “Germ Cells;” October 2004 NIH Conference: “Crossing Over;” October 2004 US Senate Appropriations Committee Staff Meeting; Derivation and propagation of human ES

cells. February 2005 Keynote Address: NIH U54 Centers for Infertility Research; April 2005 NSF AGEP Colloquim for Minority Students: Human Embryonic Stem Cells: April 2005 Endocrinology Society: June 2005 Genes of the Y chromosome; NIH conference at Asilomar; September 2005

28

Human Genetics and Stem Cell Biology: American Society for Human Genetics; October 2005 American Society for Cell Biology: November 2005 Keynote Address: Western Association of Physicians (WAP) Annual Conference; February

2006 New York State Stem Cell Foundation: Symposium on Human Embryonic Stems and Somatic

Cell Nuclear Transfer (2005) National Academies of Sciences symposium on Emerging Issues in Human Embryonic Stem Cell Research; November 2006 (Alternative methods for deriving “embryonic stem cells: Germ Cells) American Society of Reproductive Medicine (ASRM); October 2003, 2005, 2007, 2008, 2009, 2010, 2011, 2012 Panelist: World Science Festival, New York, New York: “What makes us uniquely human?”; June 2008 Panelist: World Science Festival, New York, New York: “90 is the new 50.” June 2008 National Institutes of Standards and Technology; March 2009 Gordon Research Seminars: Fertilization and Activation of Development; New Hampshire; July 2009 Agilent BioSystems, Inc; April 2012 Palo Alto Women-In Science Meeting; May 2010

Other Universities University of Washington at Seattle; Department of Genetics; October 1998 University of Wisconsin at Madison; Department of Genetics; February 1999 University of California at Irvine; Minority Students Program; November 1999 University of Virginia; Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences; March 2001 Georgetown University; Department of Cell Biology; October 2001 Cornell University, Department of Genetics and Molecular Biology; Ithaca, NY; March 2002 Whitehead Institute for Biomedical Research at MIT, Cambridge, MA; May 2002 University of Arizona in Tucson; Program for Minority Student Scientists; January 2003 Georgetown University; Department of Cell Biology; February 2003 University of Pittsburgh; Human Embryonic Stem Cell Growth; Pittsburgh Development Center, May 2003 UT-Southwestern, Green Center for Reproductive Sciences; October 2003 Keynote Address: Stanford University Genetics Retreat; October 2005 Stanford University; Reproductive Research Day; January 2000, 2001, 2002, 2003, 2004, 2005, 2006 Morehouse University, Student-Invited Speaker; February 2006 University of Connecticut; September 2006 Harvard University Stem Cell Institute (Bedford Stem Cell Symposium); November 2008 Columbia University; “Human germ line development in vivo and in vitro”; October 2009 Dominican University of California; “Ethics and stem cell biology”; February 2008 San Francisco State University; November 2008 Children’s Hospital of Oakland Research Institute (CHORI); December 2008 University of Wisconsin Superior, Alumni Association and Students: “How UWS helped me be a scientist”; June 2009 Ohio Northern University; October 2010 College of Veterinary Medicine, University of Illinois, Champagne Urbana; April 2009 University of California at Riverside; April 2010 Kansas University; August 2010 University of Connecticut; September 2010 UT-Southwestern; September 2011

29

University of California at Santa Cruz; May 2012 Wayne State University; May 2012 SELECTED POPULAR PRESS Good Morning America; “Update on infertility;” January 5, 1998 The San Francisco Chronicle; “UCSF study finds new clue to male infertility;” June 5, 2000 The Economist; “Infertility treatments;” December, 2000 The Scientist; “California steaming;” June, 2001 Forbes; “Help for male infertility;” February 18, 2002 ScienceDaily News; “From flies to humans -- male infertility;” January 15, 2003 San Jose Mercury News; “Seeking clues on fertility's window; Making choices: tests would

predict childbearing prime, helping women plan;” April 13, 2004 Contra Costa Times; “The stem cell initiative;” November 3, 2004 Inside Bay Area; “Who gets stem cell funding is the $3 billion question;” November 10, 2004 Los Angeles Times; “Stem cells carry mouse antigens;” January 15, 2005 Oakland Tribute; “Who gets stem cell funding is the $3 billion question: Bay Area scientists

studying Alzheimer’s, sickle cell anemia among those seeking cash;” April 10, 2005 Sacramento Bee; “Stem cell guidelines get mixed reception;” April 27, 2005 Center for Genetics and Society (Newsletter); “Stem cell guidelines get mixed reception: Critics

say voluntary rules are too lax;” April 27, 2005 Numerous daily newspapers; “UCSF stem cell experts discuss research aims;” June, 2005 The Scientist; Feature Article: “Stem cells…..an emerging portrait” July 4, 2005 Nature; “Stem-cell 'heroes' celebrate a series of breakthroughs;” July 7, 2005 San Francisco Chronicle; Medical schools get stem cell grants: UCSF, Stanford set for $3.7

million each; September 10, 2005 Science; News and Views: "Seeking immortality in a petri dish;" September 23, 2005 Milwaukee Journal Sentinel; “Wisconsin to house US stem cell bank;” October 1, 2005 Nature; News and Views: “The hands that guide: Good mentors deserve wider recognition;”

November 9, 2005 Medical News Today; “Activity of several embryonic stem cell genes is elevated in testicular and

breast cancers;” December 1, 2005 National Geographic News; Mouse testicles yield promising stem cells; March 24, 2006 Wall Street Journal; “Embryo stem-cell research spreads despite curbs;” April 4, 2006 The New Atlantis; “Stem cell spin;” Spring 2006Technology Review; “Stem cells reborn;”

May/June, 2006 New York Times; “Two new efforts to develop stem cell lines for study;” June 7, 2006 International Herald Tribune; “Scientists to develop stem cells from patients;” June 7, 2006 National Public Radio; “Harvard goes private for stem cell research;” June 7, 2006 USA Today; “Embryonic stem cell research before, after ‘Dolly’;” June 7, 2006 Technology Review (MIT Press); Stem cells reborn (therapeutic cloning); May/June 2006 Science; Stem cell research: Cloners get OK to proceed with caution; June 2006 Los Angeles Times; “New stem cell ethics issue emerges;” September 13, 2006 Newsweek; “Twenty women leaders;” September 25, 2006 NewScientist; “Reproduction revolution: The egg and sperm race;” October 11, 2006 PBS; Wired Science; “Stem cell explorer;” January 5, 2007 San Francisco Chronicle; “California: More stem cell research grants are on the way;” March

17, 2007 Chronicle of Higher Education; “Renee Reijo Pera, stem cell researcher, moves down the

peninsula;” February 2007 Los Angeles Times; “Embryonic stem cell research gets surprise support;” March 20, 2007 New York Times; “A conversation with Dr Renee Reijo Pera;” April 2008

30

Forbes; “What the stem cell ban reversal means for you;” September 2009 Business Week: “Embryo videos show which ones most likely to develop;” October 2010 Time Magazine: “Video highlights which embryos most likely to succeed in IVF;” October 2010 Stem cells: The growing pains of pluripotency;” May 2011 Health News: “Genetic markers may help predict fertility;” March 2012 Physician’s Organization News: “Scientists build Parkinson’s disease in a dish;” April 2011 Bloomberg News: “Google’s Brin makes strides in hunt for Parkinson’s cure;” May 2012 Forbes News: “Will Sergey Brin Cure Parkinson’s?” May 2012 Bizjournals/San Francisco: “Google’s Brin striving in hunt for Parkinson’s cure” May 2012 Morgan Freeman “Through the Wormhole”: Taped November 2012 (to appear summer 2013) LEADERSHIP HIGHLIGHTS AND PHILOSOPHY

As I consider the role of the nation’s great universities in education and research, I believe that if we educate the next generation well for their private and public lives, the rest will follow. The University will flourish and we will accomplish great things that endure, leaving a scientific, artistic and cultural legacy for generations with a business model that supports expansion, continual growth, and innovation through research. My leadership is based on service and giving. When I arrived at Stanford University, I put forth that I wanted to accomplish three things: 1) Build the world’s best research center that was based on a shared-laboratory model that enabled Stanford students, faculty, and research staff to succeed in areas they were not currently engaged, 2) develop a new graduate program that allowed us to educate our students at the crossroads of science, engineering, computer sciences and business, and 3) develop a business model for our research and educational activities that tapped into the resources of Silicon Valley to augment those we obtained from federal and state sources in order to bring our science to practical applications that change lives. The measurable outcomes: 1) We are educating the next generation – our Center for Human Pluripotent Stem Cell Research and Education has provided education to more than 400 students from Stanford and interns from the Cal State system; similarly we have just completed enrollment of our second graduate class. 2) We have enabled acquisition of greater than $150M in research funding at Stanford University in the last 5 years with additional contributions of greater than $200M from the private communities surrounding Stanford as we have built a new stem cell center with exquisite shared laboratory facilities to benefit all. Our contribution thus exceeds $350M in direct and indirect funds. 3) I am a founder and scientific director of four venture-backed private companies that aim to bring our technologies to the market. The first Auxogyn is the furthest along; the other three are in infancy. I believe that it is timely to extend these research and education accomplishments at this time to other geographical locations and student populations. I know that I am able to do so and that the Office of the Vice President for Research should focus on establishing research resources that can be broadly accessed, expand graduate student populations and impact, and build new models of funding that include federal, state, private and foundation sources. VISION Historically, the research enterprise throughout the United States has thrived; scientists and academicians have been awarded funds for research, time for inquiry and prestige within their communities locally and even nationally and internationally. Certainly, it is hoped that the research enterprise, and the academicians who engage in the research mission will continue to thrive and continue to contribute to their communities. However, the years ahead may be difficult and it is necessary for us to prepare “across the land.” Students may encounter difficulties funding their education, researchers may encounter even greater difficulties funding research and states may encounter difficulties in supporting their premiere educational

31

institutions at the levels that have been historically possible. In addition, it is clear that our overall academic mission is complex and there is a need to obtain buy-in from diverse faculty, staff, students and higher administration. Finally, there is a need to “dream big,” and make plans while avoiding the stigma that can be associated with politics, essentially a trail of broken promises that may be unrealistic and not in the best interest of the community. Thus, I apply for this position in hopes that I can contribute to the success of Montana State University. Clearly, no applicant should presume to know the community until one has gathered requisite information regarding all the strengths and potential areas for improvement. Nonetheless, from my history, I would seek to build upon the experience that I have gained from my time at each of the Institutions I have attended in my career – the University of Wisconsin – Superior, Kansas State University, Cornell University in Ithaca, NY, the Massachusetts Institute of Technology, the University of California at San Francisco and Stanford University. I would propose that it is beneficial to: 1) Enhance the research opportunities for students through enhanced internship and didactic education that integrates the sciences, business, law, nursing, engineering and policy and prepares the students to succeed beyond even their own expectations. 2) Strengthen, and indeed establish anew, strong collaborative and individual research efforts of faculty throughout the University to insure that research is enjoyable, adequately funded and intellectually rigorous as appropriate for a top tier institution that is focused on innovation. 3) Tap into the wealth of the community surrounding the University and beyond to bring innovation to applications and funding mechanisms. 4) Return our gifts at least ten-fold in terms of improved quality of life to the individual, the University, the surrounding neighborhood and the greater communities inclusive of diversity, in order to insure that all rise. This emphasis is consistent with the strategic plan that is focused on learning, discovery, engagement and integration. BRIEF BIOGRAPHY I grew up in the small town of Iron River, Wisconsin (population ~500), and am the youngest of six children. I was raised by my mother, who held down two or three jobs at any given time, as a cook for the public elementary school and nearby restaurants. Growing up, my mother stressed that she thought two things were most important for me when I grew up: First, I should marry a good man. Second, I should make sure that if I worked, I had an office. Her lessons were fundamental but so very valuable. Nonetheless, I certainly took detours before arriving where I am today.

In high school, I had little interest in science and instead focused on writing, math and frankly on extracurricular activities. I also had little interest in attending college; none of my family had done so and thus, it seemed an unnecessary waste of time. When I graduated high school, I subsequently took a job as a bookkeeper at the local Darwin Ford dealership. However, after about six months, I realized: Life may be long and I had one of the best jobs in town – there was little opportunity to move upward. With this realization, I borrowed my mother’s car and drove to the University of Wisconsin – Superior campus. I enrolled in college as a business major. I became interested in science in my junior year of college when I fulfilled my college science requirements through a course called “Human Genetics for Non-Majors.” Genetics reminded me of bookkeeping – but for human traits. I graduated with a BS in biology.

I first encountered research when I participated in three years of research at the Mille Lacs Wildlife Refuge in central Minnesota, in a study of the ruffed grouse population. A small group of us conducted a three-year survey of ruffed grouse numbers and nesting locations. Subsequently, I moved to Kansas to pursue research on flies and received an MS degree in Entomology from Kansas State University. This experience taught me that I really wanted to get a doctoral degree and through a less-than-straightforward process, I was accepted into Cornell University in Ithaca, NY, where I thrived. I obtained my doctoral degree doing thesis research

32

on mitosis in the yeast, Saccharyomyces cerevisiae. Then from there, I moved to the Massachusetts Institute of Technology to a human genetics laboratory. I obtained my first faculty position at the University of California in San Francisco and I focused my research on understanding human development, in hopes of building a map of human development via new methods and technologies that might alleviate, at least in part, some of the devastating consequences and unfortunate wastes of reproductive technologies.

I am now a Professor at Stanford University. My journey to this place was not direct – indeed, the journey from Iron River, Wisconsin, for a girl who was not interested in science could not be expected to be direct. I love Stanford – I love being at a university that combines the very best of graduate, undergraduate and professional studies with research as a foundation. I love directing the first new graduate program at Stanford University School of Medicine in more than 30 years, and focusing on fundamentals of development by combining science, engineering, law, and business. The students are among the very best in the entire world and surprise me at all times with their outstanding intellects and conscientiousness. However, with this application, I seek to begin the next phase of my career that is aimed at “going home” to the public institutions that bring opportunities to young men and women and help them do things that they never dreamed were possible. I have learned much over the years and I believe in the power of education to create opportunity, to produce research that stokes the economic engine and to increase our satisfaction in life overall. I have led major research and educational initiatives, centers and programs and am an academic leader who truly believes in serving. I bring experience from the University of Wisconsin – Superior, Kansas State University, Cornell University, the Massachusetts Institute of Technology, the University of California at San Francisco and Stanford University to my service.

renee a reijo pera, phd stanford university … renee a reijo pera, phd stanford university...

Documents